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Abstract Altered bone microstructure is a major compo-
nent of osteoporosis and bone fragility. Whilst an important
standard by which to diagnose and make treatment
decisions for osteoporosis, the evaluation of bone mineral
mass by dual-energy X-ray absorptiometry (DXA) at spine
or hip is not sufficient for understanding the complex nature
of bone microstructure nor to evaluate specific treatment
effects on cancellous and cortical bone. Various alternatives
to DXA have been developed, enabling the measurement of
bone geometry and/or microarchitecture and/or bone
strength including hip strength analysis, peripheral and
central QCT, 3D analyses of iliac crest bone biopsies, and
more recently HR-pQCT, which allows longitudinal assess-
ment of bone microstructure at the distal radius and tibia.
The efficacy of treatments for osteoporosis can be evaluated
using these techniques. A true improvement of bone
microstructure above baseline has not been demonstrated
with anti-resorptive treatments; however, they may prevent
the decay of cancellous bone and, potentially, cortical
thinning. Anabolic agents such as parathyroid hormone
(PTH) increase cancellous bone volume and cortical
thickness; however, the improvement of cortical bone
strength by PTH may be limited by an increase in cortical
porosity. Strontium ranelate has been shown to improve not
only the trabecular network but also cortical thickness,
contributing to its anti-fracture efficacy at vertebral, non-
vertebral, and hip sites.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by
low bone mass and microarchitectural deterioration of bone
tissue (which has been redefined as poor bone quality to
reflect the properties of the bone material in addition to its
microstructure), leading to bone fragility and an increased
propensity to fractures. The evaluation of bone mineral
mass (areal BMD, g/cm2) by dual-energy X-ray absorpti-
ometry (DXA) at spine or hip is the standard by which to
diagnose and make decisions about osteoporosis treatment.
T-scores<−2.5 however are not sufficient to capture the
whole population at risk, whence the need for new tools to
evaluate fracture probability, such as FRAX [1]. Bone
fragility can be better understood by examining the
complex nature of bone microstructure, with its cortical
and cancellous bone compartments that are distributed in
different proportions at the various skeletal sites [2].
For many years only quantitative computed tomogra-
phy (QCT), either centrally (spine, hip) or peripherally
(wrist), was able to appreciate non-invasively losses in
cortical and cancellous bone volumetric density (vBMD,
g/cm3). It showed that trabecular bone loss is most
prominent within the first 10 years after the menopause
(−4%/year), while cortical vBMD declines more progres-
sively (<−1%/year), with these changes actually reflecting
not only the loss of bone mineral but also of bone
microstructure [3]. Hence, a decrease of cancellous vBMD
can reflect a loss of trabeculae, i.e., a decrease of Tb
number, as well as thinning and/or loss of connectivity of
those trabeculae. Similarly, a decrease of cortical vBMD
can reflect not only a lesser degree of mineralization
within the boundaries of the periosteal and endocortical
envelope but also endocortical erosions and/or intra-
cortical (Haversian) bone remodeling leading to cortical
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porosity. Investigations on bone biopsies demonstrate that
both trabecular and cortical bone microarchitecture con-
tribute independently to vertebral fractures in men with
osteoporosis [4]. In contrast to data reported in women, in
men it is cortical porosity, and not cortical width, that is
associated with vertebral fractures when compared with
osteoporotic men without such fractures, suggesting that
the cortical deficit is different in men and in women with
fragility fractures. In post-menopausal women, vertebral
fractures are associated with low vBMD and architectural
decay of trabecular and cortical bone at the radius and
tibia, independently of spine aBMD [5].
The contribution of microstructural changes in the cortical
and trabecular bone compartments to bone fragility varies
between skeletal sites. Hence, a sharp decrease of cancellous
vBMD, reflecting a loss of trabeculae, is a strong determinant
of the rapidly rising incidence of wrist and vertebral fractures
in post-menopausal women, whereas trabeculae within the
femur neck could contribute less than 10% to the axial
compression strength of the hip [6]. In contrast, hip fractures
will be prominently determined by loss of cortical bone
vBMD and thickness, which will take many more years to
become clinically manifest due to the lower remodeling
surfaces on cortical than trabecular bone [6, 7]. From these
observations, it clearly appears that current non-invasive
evaluation of BMD, be it areal or volumetric, has limited
value in understanding the actual changes in bone micro-
structure/quality that occur in the skeleton.
Evaluation of bone structure and strength
Attempts have been made to evaluate geometrical/structural
parameters at the hip from DXA acquisitions by hip
strength analysis (HSA). This approach, based on the
distribution of apparent densities from side to side on the
2D planar image of the hip, has shown that fracture cases
have a wider neck diameter, lower cortical thickness (CTh),
and an increased buckling ratio, BR (outer radius/wall
thickness) [7]. A recent study [8] reported greater changes
in the cross-sectional area (CSA), section modulus (SM),
CTh, and BR at both the narrow neck and intertrochanteric
region from baseline to 2 years with alendronate (ALN)
compared with risedronate (RIS), paralleling the differences
observed in BMD gain between these drugs. Teriparatide
(TPT) similarly improved CSA, SM, and BR compared
with PBO [9]. HSA analysis in 483 post-menopausal
osteoporotic women from the TROPOS study showed a
5% to 8% increase in CSA, SM, and CTh and a 3%
reduction of BR in those treated with strontium ranelate
(SR) for 5 years, while these structural parameters
decreased by 2–3% and BR increased by 5% in the placebo
(PBO) group (Table 1). Similar differences were seen in all
three subregions analyzed (narrow neck, intertrochanteric,
and shaft). Moreover, CSA and CTh remained different
between SR and PBO after adjustment for BMD. HSA
however is limited by the heavy assumptions underlying it,
such as a cylindrical shape of the femur neck, the poor
definition of edge margins between the cortical and
medullary space, the large effects of even small differences
in hip rotation from one examination to the other, and, most
importantly, its dependence upon changes in bone mineral-
ization/apparent density as influenced by various drugs [10].
As an alternative to DXA, QCT offers complete 3D
information, high in plane resolution, and separate assess-
ment of cortical and trabecular bone of the femur.
Moreover, finite element analysis (FEA), which calculates
bone strength from QCT data, strongly predicts in vitro
femoral and vertebral breaking strength. The FEA strength-
to-density ratio in particular can reveal when treatment
increases strength beyond its BMD effects. Hence, consis-
tent with its bone anabolic properties, teriparatide (TPT)
was shown to increase the estimated vertebral strength and
strength-to-density ratio over alendronate after 6 and
18 months [11]. At the hip, a recently developed structural
analysis approach (QCT-PRO BIT®) showed an increase of
cortical CSA, while total CSA remained unchanged,
confirming that TPT induces endosteal but no periosteal
growth. This analysis also showed a significant decline of
hip cortical vBMD with PTH from 6 to 24 months, which
could reflect both the endocortical apposition of under-
mineralized new bone and/or increased cortical porosity
[12].
Histomorphometry and 3D microstructure of bone
biopsies
The gold standard to identify alterations in bone micro-
structure/quality and treatment effects thereon has long
been (and remains) the histomorphometrical analysis of
iliac crest bone biopsies, first by 2D conventional micros-
copy then by 3D micro-CT analysis of the biopsy cores.
This approach allows one to assess not only the finest
dimensions of the cancellous and cortical bone compart-
ments but also the dynamic parameters of bone remodeling
as evaluated by double-tetracycline labeling of bone
surfaces. In this case, the mineral apposition rate (MAR),
as evaluated by the distance between the two tetracycline
labels, reflects the bone-forming activity of osteoblasts,
whereas the mineralizing surface (MS/BS) and bone
formation rate (BFR), which depend on the extent of
single- and double-labeled surfaces, reflect the degree of
bone turnover/remodeling. Hence, bone biopsies from
patients treated with potent antiresorptives that markedly
decrease the activation frequency, such as bisphosphonates
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(and even more prominently the RANKL inhibitor denosu-
mab), show a significant reduction of MS/BS and BFR,
whereas MAR is not necessarily reduced [13–15] (Table 2).
However, the recently observed increase in MAR with ZOL
could be an overestimation caused by discarding from
analysis several bone biopsies with missing double labels.
MAR was also 9–10% greater on both trabecular and
endocortical bone surfaces in women treated with SR
compared with PBO for 2 to 5 years [16]. In contrast, due
to its mechanism of action, which differs from that of anti-
resorptives, SR did not inhibit MS/BS or BFR (Table 2).
PTH and PTH-derived molecules also tend to improve
MAR, BFR, and the mean wall thickness—a hallmark of
new bone formation—(compared with baseline) at trabec-
ular and/or endocortical surfaces [17, 18]. In a head-to-head
bone biopsy study of teriparatide vs SR for 6 months in
post-menopausal women with osteoporosis, the only bone
forming parameter to differ between the groups was the
endocortical MS/BS (TPT, n=28, 17.2%; SR, n=21, 9.7%,
p=0.052), whereas BFR and MAR were similar with both
treatments at both trabecular and endocortical surfaces [19].
3D micro-CT analysis of paired bone biopsies in 12 post-
menopausal women from the PBO group of a randomized
control trial showed that Tb bone volume decreased by 20%
and Tb number (TbN) by 13% within 1 year, while LS BMD
declined by 3% [20], whereas no statistically significant
deterioration occurred in the risedronate-treated group (n=
14). After 3 years, risedronate fully prevented the reduction
of Tb bone volume fraction (BV/TV, −27%), Tb thickness
(TbTh, −20%), and TbN (−10%) observed in a subgroup of
11 women with high bone turnover receiving PBO [21].
Histomorphometrical analyses of cross-sectional bone biop-
sies from numerous randomized, controlled trials with
bisphosphonates have also consistently reported a preserva-
tion of trabecular bone microstructure. For instance,
alendronate (ALN) and zoledronic acid (ZOL) improved
the 2D and 3D trabecular BV/TV and TbN after 3 years vs
PBO [15, 22] (Table 1). In contrast, bisphosphonates have
generally not shown a significant improvement of CTh over
time. Contrasting with anti-resorptives, agents with anabolic
properties, such as PTH/teriparatide and SR, improve not
only the trabecular bone structure but also CTh [16, 18]
N (samples) Strontium ranelate (n=251) Placebo (n=232) P
Cross-sectional area 9.05±10.65 −4.06±8.82 <0.001
CSMI 8.60±14.06 −4.81±14.63 <0.001
Section modulus 11.07±14.03 −4.72±14.77 <0.001
Endocortical diameter −1.93±3.19 −0.01±3.59 <0.001
Cortical thickness 10.27±11.57 −4.02±9.33 <0.001
Buckling ratio −10.32±10.08 5.93±22.00 <0.001
Table 1 Five-year relative
changes (%) of hip strength
analysis parameters at the
intertrochanteric site
Table 2 Bone histomorphometry in randomized, controlled trials of osteoporosis drugs
ALNa [20] PBO ZOL [13] PBO SR [14] PBO TPT [15, 16] PBO
Trabecular
MAR (µm/d) 0.63–0.70 0.59 0.60 0.53 0.62 0.57 0.56 0.57
BFR (µm3/µm2/d) 0.003–0.019 0.039 0.05 0.15 0.025 0.028 NA NA
2D-BV/TV (%) 17.1 13.4 16.9 14.2 NA NA 18.0 14.0
2D-TbN 1.19 1.07 NA NA NA NA 1.9 1.85
3D-BV/TV 19.4 16.2 16.2 12.9 17.4 15.4 13.0 11.0
3D-TbN 1.46 1.31 1.36 1.22 1.30 1.14 1.31 1.26
Endocortical
MAR (µm/d) NA NA NA NA 0.77 0.72 NA NA
BFR (µm3/µm2/d) NA NA NA NA 0.033 0.037 NA NA
2D-CTh (mm) NA NA 0.624 0.511 NA NA 1.008 0.753
3D-CTh (mm) NA NA 0.72 (0.79)b 0.63 0.727 0.615 0.92 0.74
MAR mineral apposition rate, BFR bone forming rate, BV/TV trabecular bone volume fraction, TbN trabecular number, CTh cortical thickness,
ALN alendronate, ZOL zoledronic acid, SR strontium ranelate, TPT teriparatide, PBO placebo, NA not available
a At 5 or 10 mg/d for 2 and 3 years
b A subgroup with previous non-bisphosphonate treatment (data in parentheses)
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(Table 2). At the clinically used dose, wider cortical
thickness with these agents is most certainly explained by
new bone formation at endocortical rather than periosteal
surfaces. In the head-to-head bone biopsy study of TPT vs
SR mentioned above [19], no significant differences in
parameters related to bone structure (BV/TV, TbN, TbTh,
CTh,…) were observed between the two treatments. How-
ever, cortical porosity was significantly greater with TPT
than with SR (5.4% vs 4.1%, p=0.037), reflecting the
induction of Haversian bone remodeling by TPT.
Although considered as the gold standard to evaluate
bone remodeling and microstructure, bone histomorphom-
etry has its own limitations, including the rather small
number of interpretable biopsy samples in any study, the
very few studies that have collected paired biopsies to
analyze longitudinal changes in bone turnover and micro-
structure (available only with RIS and TPT), sampling
variations, and the fact that bone remodeling at the iliac
crest could be quite different from spine or hip.
Non-invasive evaluation of bone microstructure
In order to evaluate longitudinal changes of cortical and
cancellous bone microstructure in the appendicular skeleton
from a larger number of subjects, high-resolution (micro-) CT
and MRI technologies are being developed. Although these
technologies do not yet allow the evaluation of microstructure
centrally, i.e., at spine or hip, peripheral sites such as the distal
radius and tibia are commonly analyzed. One of the first
studies to evaluate the effects of an osteoporosis drug, namely
calcitonin, on trabecular structure at the wrist (QUEST) [23]
used MRI (spatial resolution 156 × 500 µm, i.e., 20 slices
over a 1-cm volume of interest, VOI). It showed preservation
of BV/TV with this treatment compared to PBO over 2 years.
However, this study also illustrated that changes in cancel-
lous bone vary tremendously from one small region
(2.5 mm) to another within the VOI. Improved MRI
technology and a trabecular pattern recognition algorithm
led to serially volume-registered cross-sectional micro-MRI
images of the distal tibia [24], which showed a 7% BV/TV
gain in early menopausal women receiving estradiol com-
pared with no HRT. Meanwhile, pQCT at this site showed a
2% to 3% gain of cortical thickness compared to a 6% loss
without treatment.
The most rapidly spreading technology for the non-
invasive evaluation of bone microstructure is high-
resolution pQCT (Xtreme CT, Scanco, Switzerland), which
enables the simultaneous acquisition of a stack of 110
parallel CT slices with a nominal resolution of only 86 µm
(voxel size), starting approx. 1 cm and 2.2 cm from the
endplate of the radius and tibia, respectively, and extending
proximally over 0.9–1 cm (Fig. 1). The total volume of
interest is separated into a cortical and trabecular region
using a threshold of one third of the apparent cortical bone
density (Dcort, mg HA/cm
3) to define the cancellous bone
region. In addition to the volumetric densities in these two
compartments, HR-pQCT provides an indirect measure-
ment of TbN by evaluating the mean 3D distance between
the mid-axes of trabeculae and of CTh by dividing the
cortical volume by the outer bone surface (i.e., the cortical
area by the perimeter of each slice). The other micro-
structural values provided, such as BV/TV, TbTh, and Tb
separation (TbSp), are all derived from the above and
therefore not independent of the apparent Tb bone density
or number. Hence, the best correlated measures between
MRI and HR-pQCT are TbN and CTh, although the latter
appears systematically wider when evaluated by MRI [25].
Moreover, bone microarchitecture evaluated at the distal
radius or tibia by HR-pQCT correlates rather poorly with
3D measures of iliac crest bone biopsies (R=0.5 or less)
[26]. Trabecular thickness in particular cannot be measured
directly by HR-pQCT because of partial volume effects. In
addition, whereas the CV of repeated measures is low for
Fig. 1 a X-ray of distal tibia shows location of the VOI between
green lines for analysis of vBMD and microarchitecture by HR-pQCT.
b 3D-image of bone microstructure at distal tibia in a 25-year-old
woman with Crohn’s disease and a vertebral fragility fracture. In her
case, aBMD by DXA was normal (T-sc. LS −1.0, FN −0.4), whereas
BV/TV (10.8%) was in the lowest quintile of normal values for age/sex
S440 Osteoporos Int (2010) 21:[Suppl2]S437–S442
volumetric densities and CTh (≤1%), it is in the range of 3–
5% for TbN and the derived parameters.
Cross-sectional and some longitudinal studies have now
shown the differences in bone microstructure at the distal
radius between women and men, the latter having a greater
BV/TVand TbTh whereas the former lose TbN and CTh and
increase TbSp more rapidly than men with age [27–29].
Moreover, volumetric densities and CTh have been reported
to be inversely correlated with menarcheal age in young
women [30], which emphasizes the major role of gonadal
steroids in bone microstructure. Lower total and trabecular
bone density, BV/TV, TbN, and CTh predominantly at the
distal radius (more than at distal tibia), has been reported in
relation to both fragility fractures, including wrist fractures,
in post-menopausal women[3, 31, 32] and to traumatic
fractures of childhood/adolescence in young women. Al-
though HR-pQCT parameters are significantly correlated
with aBMD at the same site (ultra-distal radius) or a
proximal site (hip vs distal tibia) (R values ranging from
0.2–0.3 to 0.7–0.8), some of the associations between poor
trabecular microstructure and fractures remained significant
after adjustment for aBMD [33].
This technique is now also being used to evaluate
treatment effects on bone microarchitecture. In a random-
ized, double-blind, double-dummy, head-to-head compari-
son between ALN and SR in 88 post-menopausal
osteoporotic women (mean age 64, FN T-score −3.8–3.9),
changes of bone microarchitecture at distal radius and tibia
were analyzed at 3, 6, 12, and 24 months. The expected
changes occurred for bone turnover markers, i.e., a 58%
and 35% decrease of sCTx and bALP, respectively, with
ALN, and minimal opposite changes with SR (sCTx −6.6%,
bALP +5%), as well as for BMD (LS +5.1% and +4.6;
FN +3.6 and +2.7%, with SR and ALN, respectively). At the
distal tibia, CTh increased significantly more with SR than
ALN at 1 year (+5.4 vs +1.3%, p=0.045). Significant
differences were already detectable after 3 months, i.e., a
time when deposition of SR in newly formed bone is still
probably minimal and unlikely to influence the apparent
bone density. Moreover, cortical vBMD remained similar
between the two treatments (758 and 749 mg HA/cm3). After
1 year, trabecular BV/TV was also significantly greater with
SR compared to ALN (2.2% vs 0.8%, p<0.05), although as
explained above BV/TV is directly dependent on the
trabecular vBMD. Note that the distal radius microstructural
parameters were uninterpretable because of motion artifacts
during data acquisition.
Conclusions
Studies of bone microstructure using iliac crest bone
biopsies and, more recently, non-invasive techniques such
as high-resolution MRI and pQCT highlight the major
changes occurring after menopause, most prominently the
loss of trabecular number and cancellous bone volume and
the more progressive loss of cortical thickness. Altered
bone microstructure in turn is a major component of
osteoporosis and bone fragility. Anti-resorptives may
prevent the decay of cancellous bone and, potentially,
cortical thinning, although a true improvement of bone
microstructure above baseline has never been demonstrated
with these drugs. In contrast, bone-building agents such as
PTH/teriparatide promote new bone formation at both
trabecular and endocortical surfaces, resulting in a net
increase of cancellous bone volume and cortical thickness
and an improvement of bone strength, as estimated by FEA
and other analyses of QCT acquisitions in vertebrae and the
hip. However, the improvement of cortical bone strength by
PTH/teriparatide may be limited by an increase in cortical
porosity. SR on the other hand has been shown to improve
not only the trabecular network but also cortical thickness
by a variety of methods, including HSA, 3D microstructural
analyses of iliac crest bone biopsies, and, most interesting-
ly, longitudinal assessment of bone microstructure at the
distal tibia by HR-pQCT. In turn, these positive changes of
bone (micro-)structure will contribute to SR anti-fracture
efficacy at both vertebrae and non-vertebral sites, including
in the oldest women.
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